Journal article
Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study
KL Ong, R O'Connell, AS Januszewski, AJ Jenkins, A Xu, DR Sullivan, PJ Barter, RS Scott, MR Taskinen, B Waldman, PG Colman, JD Best, JR Simes, KA Rye, AC Keech
Clinical Chemistry | OXFORD UNIV PRESS INC | Published : 2017
Abstract
BACKGROUND: It is not known whether circulating fibroblast growth factor 21 (FGF21) concentrations are associated with glycemic progression in patients with established type 2 diabetes. This study reports this relationship in type 2 diabetes patients participating in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. METHODS: Plasma FGF21 was quantified in 9697 study participants. Among patients with lifestyle-only glucose control measures at baseline, glycemic progression was defined as the initiation of oral hypoglycemic agents or insulin therapy. We assessed the relationship of FGF21 concentrations with glycohemoglobin (Hb A1c), the homeostasis model assessment of ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The measurement of FGF21 concentrations in the FIELD samples was supported by a Grant-in-Aid (G 12S 6681) and the NSW CVRN Research Development Project Grant (100715) both from the National Heart Foundation of Australia. K.L. Ong, Program grants (482800 & 1037903) from the National Health and Medical Research Council (NHMRC) of Australia, Vice-Chancellor's Postdoctoral Fellowship from the University of New South Wales, and the NHMRC Career Development Fellowship (1122854). A.C. Keech, NHMRC Program grant (1037786) and Fellowship grant (1024105). Expert Testimony: None declared.